In short
EHL BIO was licensed by MFDS as Korea's first human cell processing business, manufactures cells in GMP facilities and develops programmes through MFDS-approved clinical trials. Services follow Korean law after individual physician assessment.
Approved clinical trials
ADSTEM received Phase 3 IND approval after publishing Phase 2 results, and KDSTEM received Phase 1 IND approval (in research).
What to expect
The goal is to support recovery and help symptoms or function improve where suitable. Results vary between people and a full cure is not guaranteed.
